Results 1 to 10 of about 8,967 (163)
The β‐Lactams Strike Back: Ceftazidime‐Avibactam [PDF]
Pharmacotherapy, 2015 Gram‐negative resistance has reached a crucial point, with emergence of pathogens resistant to most or all available antibiotics. Ceftazidime‐avibactam is a newly approved agent combining ceftazidime and a novel β‐lactamase inhibitor with activity against multidrug‐resistant gram‐negative bacteria.
Evan Zasowski, Jeffrey M Rybak
exaly +3 more sources
Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
Antibiotics, 2023 Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and ...
Alessandro Mancuso +5 more
doaj +4 more sources
KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae. [PDF]
PLoS ONEBackgroundGlobal surveillance indicates rising ceftazidime-avibactam resistance among carbapenem-resistant Klebsiella pneumoniae (CRKP), with sequence type 11 predominating in China. The contribution of blaKPC variants and porin alterations to high-level
Shulong Zhao +6 more
doaj +2 more sources
Revista Española de Quimioterapia, 2021 Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire +2 more sources
In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
Frontiers in Microbiology, 2021 Ceftazidime/avibactam is an important treatment option for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), however, resistance can emerge during treatment.
Yanqin Huang +8 more
doaj +1 more source
Ceftazidime-avibactam in ceftazidime-resistant infections [PDF]
The Lancet Infectious Diseases, 2016 One of the important causes of the development of resistance to β-lactam drugs is their overuse. β-lactamase inhibitors have been combined with many β-lactam drugs to resume their efficacy since the emergence of multidrugresistant organisms. Yahuda Carmeli and colleagues recommended the combination of ceftazidimeavibactam as a potential alternative to ...
Yehuda, Carmeli +4 more
openaire +5 more sources
Frontiers in Pharmacology, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Dan Li +8 more
doaj +1 more source
Antibiotics, 2021 β-lactam–avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula.
Moonsuk Bae +12 more
doaj +1 more source
Antibiotics, 2021 Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies.
Snehal Palwe +5 more
doaj +1 more source
BMC Microbiology, 2021 Background Resistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in bla KPC. Results We report the mutated bla KPC is not the only mechanism
Lingxiao Sun +4 more
doaj +1 more source